Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
2007 1
2009 1
2012 1
2013 2
2015 1
2016 2
2017 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness.
Horne BD, Ali R, Midwinter D, Scott-Wilson C, Crim C, Miller BE, Rubin DB. Horne BD, et al. Among authors: scott wilson c. Int J Chron Obstruct Pulmon Dis. 2021 Jan 7;16:41-51. doi: 10.2147/COPD.S279645. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33447025 Free PMC article. Clinical Trial.
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C. Siler TM, et al. Among authors: scott wilson ca. Respir Med. 2017 Feb;123:8-17. doi: 10.1016/j.rmed.2016.12.001. Epub 2016 Dec 2. Respir Med. 2017. PMID: 28137501 Free article. Clinical Trial.
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C. Bhatt SP, et al. Among authors: scott wilson ca. Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:351-365. doi: 10.2147/COPD.S117373. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28176907 Free PMC article. Clinical Trial.
Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM. Cowie RL, et al. Among authors: scott wilson ca. Clin Ther. 2007 Jul;29(7):1390-402. doi: 10.1016/j.clinthera.2007.07.021. Clin Ther. 2007. PMID: 17825690 Clinical Trial.
11 results